UBS Group’s Bone Biologics BBLG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-56
| Closed | -$62 | – | 10446 |
|
|
2026
Q1 | $62 | Sell |
56
-1,892
| -97% | -$2.6K | ﹤0.01% | 10180 |
|
|
2025
Q4 | $2.83K | Buy |
1,948
+1,882
| +2,852% | +$3.75K | ﹤0.01% | 9215 |
|
|
2025
Q3 | $184 | Sell |
66
-47
| -42% | -$119 | ﹤0.01% | 9831 |
|
|
2025
Q2 | $455 | Buy |
+113
| New | +$522 | ﹤0.01% | 9823 |
|
|
2025
Q1 | – | Sell |
-3,644
| Closed | -$20.6K | – | 10230 |
|
|
2024
Q4 | $20.6K | Sell |
3,644
-1,831
| -33% | -$15.1K | ﹤0.01% | 7850 |
|
|
2024
Q3 | $70K | Sell |
5,475
-143
| -3% | -$1.35K | ﹤0.01% | 6597 |
|
|
2024
Q2 | $41.1K | Buy |
5,618
+5,518
| +5,518% | +$54.5K | ﹤0.01% | 6842 |
|
|
2024
Q1 | $1.28K | Buy |
+100
| New | +$1.95K | ﹤0.01% | 8168 |
|
|
2023
Q4 | – | Sell |
-3
| Closed | -$96 | – | 9303 |
|
|
2023
Q3 | $96 | Buy |
+3
| New | +$149 | ﹤0.01% | 8896 |
|
|
2023
Q2 | – | Sell |
-30
| Closed | -$11.3K | – | 8915 |
|
|
2023
Q1 | $11.3K | Buy |
30
+19
| +173% | +$7.93K | ﹤0.01% | 7516 |
|
|
2022
Q4 | $3.21K | Buy |
+11
| New | +$6.2K | ﹤0.01% | 9548 |
|
|
2022
Q3 | – | Sell |
-5
| Closed | -$11K | – | 10324 |
|
|
2022
Q2 | $11K | Buy |
+5
| New | +$13.2K | ﹤0.01% | 7783 |
|
|
2022
Q1 | – | Hold |
0
| – | – | – | 10245 |
|
Other funds holding BBLG
UBS Group's BBLG Position: Q2 2026 in Review
UBS Group sold out of Bone Biologics (BBLG) in Q2 2026, closing a stake of 56 shares — an estimated $62 sold.
UBS Group first reported a position in BBLG in Q2 2022 and held it in 12 quarters. The position peaked at $70K in Q3 2024. 3 funds tracked by Wall St. Rank hold BBLG as of Q2 2026.
- UBS Group reported no remaining Bone Biologics position as of Q2 2026 after selling out during the quarter.
- UBS Group sold 56 Bone Biologics shares in Q2 2026, an estimated $62.
- UBS Group first reported a position in Bone Biologics in Q2 2022 and held it in 12 quarters.
- UBS Group's Bone Biologics position peaked at $70K in Q3 2024.
- 3 funds tracked by Wall St. Rank held Bone Biologics as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.